A-1210477

Target: This ligand targets anti-apoptotic protein MCL-1 in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for anti-apoptotic protein MCL-1. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings anti-apoptotic protein MCL-1 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Degradation Studies: A-1210477 can be used as a ligand component in PROTAC constructs to recruit an E3 ubiquitin ligase and drive selective degradation of a chosen target protein. This enables systematic evaluation of ternary complex formation, ubiquitination efficiency, and degradation kinetics across cell models and engineered reporter systems.

• Target Engagement Optimization: Incorporating A-1210477 into PROTAC designs supports optimization of target engagement by tuning linker length, attachment position, and overall physicochemical properties. Researchers can use degradation readouts to infer productive binding modes, compare residence-time effects, and refine construct parameters that maximize target turnover while minimizing off-target degradation.

• Mechanistic Ubiquitin Pathway Probing: A-1210477-based PROTACs can be applied to dissect the ubiquitin-proteasome dependency of degradation. By combining pharmacological inhibitors or genetic perturbations of E3 ligase components, investigators can quantify how ubiquitination and proteasomal processing contribute to the observed loss of target protein abundance.

• Comparative Ligand Recruitment Profiling: Using A-1210477 in PROTAC panels facilitates head-to-head comparisons of ligand-driven recruitment potency and degradation efficiency. This approach helps map how ligand affinity and orientation influence ternary complex stability, determine whether degradation is driven by cooperative binding, and identify conditions that favor rapid, sustained target depletion.

A-1210477 is a BCL-family protein ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of A-1210477 is characterized by carboxylic acid or carboxylate handle; primary or secondary amine/basic nitrogen centers; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The acid handle supports amide coupling with amino-PEG, alkyl-diamine, piperazine, or aminoalkyl E3-ligase ligands. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.